Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Page Path

HOME
ARTICLE CATEGORY
Editorial

Editorial

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2021;27(3):448-450. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0130

View: 3993 Download: 121 Web of Science: 2 Crossref: 1

An analysis of polygenic risk scores for non-alcoholic fatty liver disease

Dae Won Jun

Clin Mol Hepatol. 2021;27(3):446-447. Published online May 21, 2021

DOI: https://doi.org/10.3350/cmh.2021.0133

View: 4449 Download: 155 Web of Science: 5 Crossref: 5

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

View: 3739 Download: 101 Web of Science: 5 Crossref: 5

Biopsy or cytology for diagnosing hepatic focal lesions?

Haeryoung Kim

Clin Mol Hepatol. 2021;27(2):278-280. Published online March 4, 2021

DOI: https://doi.org/10.3350/cmh.2021.0031

View: 3634 Download: 76 Web of Science: 1 Crossref: 1

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2021;27(2):273-277. Published online February 1, 2021

DOI: https://doi.org/10.3350/cmh.2021.0019

View: 4542 Download: 136 Web of Science: 5 Crossref: 6

A need for patient-centered care in managing patients with liver cirrhosis

Eileen L. Yoon

Clin Mol Hepatol. 2021;27(2):270-272. Published online January 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0001

View: 3580 Download: 111 Web of Science: 2 Crossref: 2

Old hepatitis B virus never dies: It just hides itself within the host genome

Jeong-Hoon Lee

Clin Mol Hepatol. 2021;27(1):107-109. Published online December 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0324

View: 3801 Download: 114 Web of Science: 4 Crossref: 3

Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma

Jun Won Kim, Ik Jae Lee

Clin Mol Hepatol. 2021;27(1):103-106. Published online December 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0297

View: 3991 Download: 97 Crossref: 1

Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care

Seong Hee Kang, Moon Young Kim

Clin Mol Hepatol. 2021;27(1):100-102. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0312

View: 4565 Download: 77 Web of Science: 5 Crossref: 5

Elimination of hepatitis C: What would be the practical approach?

Hyung Joon Yim

Clin Mol Hepatol. 2021;27(1):97-99. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0304

View: 5347 Download: 119 Web of Science: 2 Crossref: 2

Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever

Marta Tonon, Salvatore Piano

Clin Mol Hepatol. 2021;27(1):94-96. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0305

View: 4438 Download: 141 Web of Science: 7 Crossref: 7

The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?

Beom Kyung Kim

Clin Mol Hepatol. 2021;27(1):91-93. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0311

View: 3782 Download: 88 Web of Science: 5 Crossref: 6

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0302

View: 4926 Download: 108 Web of Science: 12 Crossref: 13

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan

Clin Mol Hepatol. 2021;27(1):83-86. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0298

View: 4905 Download: 160 Web of Science: 1 Crossref: 1

Drug-drug interactions with direct-acting antivirals — less is more

Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(1):81-82. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0278

View: 3824 Download: 103 Web of Science: 1 Crossref: 1

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Paul Kwo, Deepti Dronamraju

Clin Mol Hepatol. 2020;26(4):489-491. Published online September 24, 2020

DOI: https://doi.org/10.3350/cmh.2020.0228

View: 3983 Download: 69 Web of Science: 1 Crossref: 1

Acute-on-chronic liver failure: A predictor of poor prognosis in patients with variceal bleeding or a risk factor for variceal bleeding?

Nae-Yun Heo

Clin Mol Hepatol. 2020;26(4):487-488. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0209

View: 3843 Download: 103 Web of Science: 2 Crossref: 2

Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma

Jaewhan Song

Clin Mol Hepatol. 2020;26(4):484-486. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0220

View: 6038 Download: 137 Web of Science: 9 Crossref: 9

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

DOI: https://doi.org/10.3350/cmh.2020.0208

View: 5289 Download: 98 Web of Science: 12 Crossref: 11

Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma

Sooyeon Oh, Jooho Lee

Clin Mol Hepatol. 2020;26(4):476-479. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0192

View: 4922 Download: 152 Web of Science: 12 Crossref: 11

Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?

Jung Hee Kim, Dong Hyun Sinn

Clin Mol Hepatol. 2020;26(3):315-317. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0084

View: 4782 Download: 105 Crossref: 1

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 5153 Download: 125 Crossref: 2

Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?

So Yeon Kim

Clin Mol Hepatol. 2020;26(3):309-311. Published online June 15, 2020

DOI: https://doi.org/10.3350/cmh.2020.0061

View: 4952 Download: 101 Web of Science: 5 Crossref: 5

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

Sojung Han, Do Young Kim

Clin Mol Hepatol. 2020;26(3):305-308. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0096

View: 4377 Download: 110 Web of Science: 5 Crossref: 5

Is liver biopsy still useful in the era of non-invasive tests?

Tae Seop Lim, Ja Kyung Kim

Clin Mol Hepatol. 2020;26(3):302-304. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0081

View: 4405 Download: 134 Web of Science: 10 Crossref: 11

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?

Soung Won Jeong

Clin Mol Hepatol. 2020;26(2):185-186. Published online March 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0046

View: 4560 Download: 89 Web of Science: 1 Crossref: 2

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?

Ju Hyun Shim

Clin Mol Hepatol. 2020;26(2):183-184. Published online March 12, 2020

DOI: https://doi.org/10.3350/cmh.2020.0042

View: 4378 Download: 113 Web of Science: 6 Crossref: 6

Should physicians go out of the way to differentiate between acute hepatitis B and acute exacerbation of chronic hepatitis B?

Hyun Woong Lee

Clin Mol Hepatol. 2020;26(2):180-182. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0045

View: 4247 Download: 107

A leap for the journal: Clinical and Molecular Hepatology enters a new era

Yoon Jun Kim

Clin Mol Hepatol. 2019;25(4):333-334. Published online December 17, 2019

DOI: https://doi.org/10.3350/cmh.2019.1004

View: 4243 Download: 57

How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?

Jung Hwan Yu, Jin-Woo Lee

Clin Mol Hepatol. 2019;25(3):280-282. Published online January 21, 2019

DOI: https://doi.org/10.3350/cmh.2018.0104

View: 5632 Download: 125 Web of Science: 1 Crossref: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

09 Days

Publication after acceptance

03 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 5504	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5404	MAFLD: How is it different from NAFLD?
Viewed By 5214	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5094	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4725	Global incidence and prevalence of nonalcoholic fatty liver disease

MOST CITED (2022-2024)

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 208

TOTAL : 1931311